Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IVERIC BIO, INC.

(ISEE)
  Report
Real-time Estimate Cboe BZX  -  01:51 2022-11-29 pm EST
23.01 USD   +3.16%
11/28Iveric Bio, Inc. : Other Events (form 8-K)
AQ
11/18Sector Update: Health Care Stocks Finishing Near Friday Session Highs
MT
11/18Top Midday Gainers
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Iveric Bio : Investor Day June 2021

06/18/2021 | 02:03pm EST

Welcome to Today's Virtual Symposium for Investors and Analysts

Forward-looking statements

The presentations today include forward-looking statements of IVERIC bio, Inc. (the "Company"). Any statements about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company's strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend", "goal," "future", "may", "might," "plan," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. In the presentations today, the Company's forward looking statements include statements about the timing, progress and results of clinical trials, including expectations regarding patient enrollment and retention in GATHER2, the Company's development strategy for Zimura and IC-500, including their potential development in other forms or stages of dry age-related macular degeneration, the Company's hypotheses regarding complement inhibition and inhibition of HtrA1 as mechanisms of action to treat GA and other forms of dry AMD, estimates regarding the number of patients the Company's product candidates are intended to treat, and the utility of Zimura and IC-500. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and

uncertainties include, among others, those related to the progression and duration of the COVID-19 pandemic and responsive

measures thereto and related effects on the Company's research and development programs, operations and financial position, the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, expectations for regulatory matters, reliance on clinical trial sites, contract research organizations and other third parties, developments from the Company's competitors and the marketplace for its products, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the "Risk Factors" section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company's views only as of today. The Company anticipates that subsequent events and developments may cause its views to

change. While the Company may elect to update these forward-looking statements at some point in the future, the Company

specifically disclaims any obligation to do so except as required by law.

2

Financial disclosures

Frank G. Holz, MD

Peter K. Kaiser, MD

Arshad M. Khanani, MD, MA

Anat Loewenstein, MD

Vas R. Sadda, MD

Trent M. Woodruff, PhD

Charles C. Wykoff, MD, PhD

Grants: Centervue, Ellex, NightStarXOptos

Grants and consultant/advisor: Acucela, Allergan, Apellis, Bayer, Bioeq/Formycon, Roche/Genentech, Geuder, Heidelberg Engineering, Iveric Bio, Kanghong, Novartis, Zeiss

Consultancy/advisor: Boehringer-Ingelheim, Graybug Vision, LinBioscience, Pixium Vision, Stealth BioTherapeutics, Aerie, Oxurion

Consultant: Aerie, Allegro, Allergan, Allgenesis, Alzheon, Annexon Biosciences, AsclepiX, Aviceda, Bayer, Bausch and Lomb, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, DelSiTech, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Gemini Therapeutics, Glaukos, Innovent, iRenix, IvericBio, jCyte, Kanaph Therapeutics, Kanghong, Kodiak, LensGen, NGM Biopharmaceuticals, Inc., Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra Therapeutics Inc., Omeros, Opthea, Oxurion, Palatin, Regeneron, RegenxBio, Retinal Sciences, Retrope, Roivant, Samsung Bioepis, Sandoz, Santen, Stealth Biotherapeutics, Sustained Nano Systems, Takeda, Théa, 2020 Onsite

Consultant: Adverum, Aerpio, Allergan, Chengdu Kanghong, Dutch Ophthalmic Research Center, Genentech, Inc., Kato, Kodiak, Novartis, Gemini, Graybug, Gyroscope, Opthea, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Roche

Research support: Adverum, Alkahest, Allegro, Allergan, Chengdu Kanghong, Gemini, Genentech, Inc., Gyroscope, Iveric Bio, NGM, Kodiak, Novartis, Opthea, Oxurion, Regenxbio, Recens Medical, Roche

Lecture fees: Allergan, Genentech, Novartis

Consultant: Allergan, Bayer Health Care, Beyeonics, Forsightlabs, Notal Vision, Novartis, Roche

Consultant: Allergan, Amgen, Iveric, Apellis, Bayer, Merck, 4DMT, Roche/Genentech, Novartis, Oxurion, Regeneron, NightstaRX, Optos, CenterVue, Heidelberg

Research instruments: Topcon, Nidek, Carl Zeiss Meditec, Heidelberg, CenterVue, Optos

Consultant: Alexion, Alsonex, Visterra, Clearview, Mabylon, Annexon

Consultant: Adverum, Aerie Pharmaceuticals, Allergan, Allgenesis, Apellis, Arctic Vision, Arrowhead Pharmaceuticals, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, EyePoint Pharmaceuticals, Genentech, Gyroscope, IVERIC Bio, Kato Pharmaceuticals, Kodiak Sciences, Long Bridge Medical, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea Limited, Oxurion, Palatin, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, SAI MedPartners, Surrozen Takeda, Verana Health

Research: Adverum, Aerie Pharmaceuticals, Aldeyra, Alimera Sciences, Allergan, Amgen, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, iRENIX, IVERIC bio, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Oxurion, RecensMedical, Regeneron, RegenXBio, Roche, SamChunDang Pharm, Taiwan Liposome Company, Xbrane BioPharma

Ownership/Stock: ONL Therapeutics, PolyPhotonix, RecensMedical, Visgenx

3

Welcome to Today's Virtual Symposium for Investors and Analysts

GLENN P. SBLENDORIO

Chief Executive Officer, Iveric Bio

Virtual Symposium for Investors and Analysts

PRAVIN U. DUGEL, MD

President, Iveric Bio

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Iveric Bio Inc. published this content on 18 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2021 18:02:08 UTC.


ę Publicnow 2021
All news about IVERIC BIO, INC.
11/28Iveric Bio, Inc. : Other Events (form 8-K)
AQ
11/18Sector Update: Health Care Stocks Finishing Near Friday Session Highs
MT
11/18Top Midday Gainers
MT
11/18Sector Update: Health Care Stocks Underpinning Friday Markets
MT
11/18IVERIC bio Secures FDA's Breakthrough Therapy Designation for Potential Drug for Geogra..
MT
11/18Sector Update: Health Care
MT
11/18After Two Losing Sessions, Markets Set to Open Friday Trading Higher
MT
11/18Sector Update: Health Care Stocks Advance Pre-Bell Friday
MT
11/18Sector Update: Health Care
MT
11/18Markets Look to Reverse Two Days of Losses as US Futures Trend Higher Pre-Bell
MT
More news
Analyst Recommendations on IVERIC BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -177 M - -
Net cash 2022 272 M - -
P/E ratio 2022 -15,2x
Yield 2022 -
Capitalization 2 692 M 2 692 M -
EV / Sales 2022 -
EV / Sales 2023 169x
Nbr of Employees 148
Free-Float 98,7%
Chart IVERIC BIO, INC.
Duration : Period :
IVERIC bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IVERIC BIO, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 22,30 $
Average target price 29,17 $
Spread / Average Target 30,8%
EPS Revisions
Managers and Directors
Glenn P. Sblendorio Chief Executive Officer & Director
Pravin U. Dugel President
David F. Carroll Chief Financial Officer, Treasurer & Senior VP
Adrienne L. Graves Chairman
Xiao Ping Dai Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
IVERIC BIO, INC.33.37%2 692
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
SEAGEN INC.-21.59%22 506